43769 recent Wall Street rating changes — with our own star rating shown next to every analyst we independently track.
Track the latest analyst rating changes from Wall Street brokerages: stock upgrades, downgrades and price-target revisions, updated through the day. Unlike a plain ratings feed, every change here is matched — where we can — to the analyst's independent track record on 13Foresight, so you can see at a glance whether the person behind the call has actually been accurate. Analysts we rank show a ★★★★☆ score and link to their full performance page; firms link to their pooled track record. Use the tabs below to filter by change type.
| When | Stock | Change | Analyst | Rating | Price Target |
|---|---|---|---|---|---|
|
Aug 08
11:33 UTC
|
JHX
James Hardie Industries
|
◎ Target | Tyler Batory ★★★★☆ #364 | Outperform | $32.00→ $36.00+12.5% |
|
Aug 08
11:33 UTC
|
JANX
Janux Therapeutics
|
◎ Target | Brad Canino not yet tracked | Buy | $58.00→ $55.00-5.2% |
|
Aug 08
11:33 UTC
|
ITT
ITT
|
◎ Target | Jeffrey Hammond ★★★☆☆ #2184 | Overweight | $250.00→ $263.00+5.2% |
|
Aug 08
11:33 UTC
|
ITT
ITT
|
◎ Target | Vladimir Bystricky not yet tracked | Buy | $254.00→ $267.00+5.1% |
|
Aug 08
11:33 UTC
|
IRTC
iRhythm Technologies
|
◎ Target | Nathan Treybeck ★★☆☆☆ #2310 | Overweight | $180.00→ $168.00-6.7% |
|
Aug 08
11:33 UTC
|
IRTC
iRhythm Technologies
|
◎ Target | David Saxon ★★★★★ #280 | Buy | $255.00→ $192.00-24.7% |
|
Aug 08
11:33 UTC
|
IRD
Opus Genetics
|
◎ Target | Lisa Walter ★★☆☆☆ #2557 | Outperform | $10.00→ $9.00-10.0% |
|
Aug 08
11:33 UTC
|
IOVA
Iovance Biotherapeutics
|
◎ Target | Etzer Darout ★★★☆☆ #1100 | Overweight | $11.00→ $13.00+18.2% |
|
Aug 08
11:33 UTC
|
IOVA
Iovance Biotherapeutics
|
◎ Target | Reni J. Benjamin not yet tracked | Market Outperform | $5.00→ $8.00+60.0% |
|
Aug 08
11:33 UTC
|
INVA
Innoviva
|
◎ Target | Steve Seedhouse not yet tracked | Overweight | $36.00→ $34.00-5.6% |
|
Aug 08
11:33 UTC
|
INSM
Insmed
|
◎ Target | Vamil Divan ★★★☆☆ #1009 | Buy | $207.00→ $205.00-1.0% |
|
Aug 08
11:33 UTC
|
INSM
Insmed
|
◎ Target | Benjamin Burnett ★★★☆☆ #2056 | Overweight | $161.00→ $169.00+5.0% |
|
Aug 08
11:33 UTC
|
IFRX
InflaRx
|
◎ Target | Steve Seedhouse not yet tracked | Overweight | $4.00→ $6.00+50.0% |
|
Aug 08
11:33 UTC
|
IFF
International Flavors & Fragrances
|
◎ Target | Lauren Lieberman ★★★★☆ #887 | Overweight | $90.00→ $96.00+6.7% |
|
Aug 08
11:33 UTC
|
ICUI
ICU Medical
|
◎ Target | Sam Eiber ★★☆☆☆ #2313 | Buy | $170.00→ $200.00+17.6% |
|
Aug 08
11:33 UTC
|
ICUI
ICU Medical
|
◎ Target | Jason Bednar ★★★★☆ #346 | Overweight | $163.00→ $195.00+19.6% |
|
Aug 08
11:33 UTC
|
ICUI
ICU Medical
|
◎ Target | Mike Matson not yet tracked | Buy | $165.00→ $187.00+13.3% |
|
Aug 08
11:33 UTC
|
HWM
Howmet Aerospace
|
◎ Target | Ken Herbert not yet tracked | Outperform | $325.00→ $350.00+7.7% |
|
Aug 08
11:33 UTC
|
HWM
Howmet Aerospace
|
◎ Target | Charles Minervino ★★★☆☆ #1280 | Positive | $330.00→ $340.00+3.0% |
|
Aug 08
11:33 UTC
|
HWM
Howmet Aerospace
|
◎ Target | Gavin Parsons ★★★☆☆ #1354 | Neutral | $299.00→ $326.00+9.0% |
|
Aug 08
11:33 UTC
|
HUBS
HubSpot
|
◎ Target | Tyler Radke ★★★★☆ #357 | Buy | $217.00→ $210.00-3.2% |
|
Aug 08
11:33 UTC
|
HSX
Hiscox
|
◎ Target | firm only | Buy | GBX 1,900→ GBX 2,150+13.2% |
|
Aug 08
11:33 UTC
|
HSBA
HSBC
|
◎ Target | firm only | Neutral | GBX 1,380→ GBX 1,450+5.1% |
|
Aug 08
11:33 UTC
|
HRZN
Horizon Technology Finance
|
◎ Target | Mitchel Penn ★☆☆☆☆ #3082 | Market Perform | $6.00→ $5.00-16.7% |
|
Aug 08
11:33 UTC
|
HR
Healthcare Realty Trust
|
◎ Target | Michael Carroll ★★★★★ #321 | Sec→ r Perform | $21.00→ $22.00+4.8% |
|
Aug 08
11:33 UTC
|
HPP
Hudson Pacific Properties
|
◎ Target | Richard Anderson ★★★★☆ #573 | Overweight | $14.00→ $17.00+21.4% |
|
Aug 08
11:33 UTC
|
HP
Helmerich & Payne
|
◎ Target | Charles Minervino ★★★☆☆ #1280 | Positive | $40.00→ $44.00+10.0% |
|
Aug 08
11:33 UTC
|
HGTY
Hagerty
|
◎ Target | Mark Hughes ★★★★☆ #663 | Hold | $11.00→ $13.00+18.2% |
|
Aug 08
11:32 UTC
|
HG
Hamilton Insurance Group
|
◎ Target | Matthew J. Carletti not yet tracked | Market Outperform | $40.00→ $42.00+5.0% |
|
Aug 08
11:32 UTC
|
HCI
HCI Group
|
◎ Target | Matthew J. Carletti not yet tracked | Market Outperform | $255.00→ $265.00+3.9% |
|
Aug 08
11:32 UTC
|
HASI
HA Sustainable Infrastructure Capital
|
◎ Target | Mark Strouse ★★☆☆☆ #2631 | Overweight | $50.00→ $51.00+2.0% |
|
Aug 08
11:32 UTC
|
HASI
HA Sustainable Infrastructure Capital
|
◎ Target | Jon Windham ★★☆☆☆ #2433 | Buy | $50.00→ $51.00+2.0% |
|
Aug 08
11:32 UTC
|
HALO
Halozyme Therapeutics
|
◎ Target | Brendan Smith ★★★★★ #101 | Buy | $96.00→ $105.00+9.4% |
|
Aug 08
11:32 UTC
|
HALO
Halozyme Therapeutics
|
◎ Target | Mohit Bansal ★★★☆☆ #1400 | Equal Weight | $75.00→ $95.00+26.7% |
|
Aug 08
11:32 UTC
|
HALO
Halozyme Therapeutics
|
◎ Target | Mitchell S. Kapoor not yet tracked | Buy | $95.00→ $115.00+21.1% |
|
Aug 08
11:32 UTC
|
HALO
Halozyme Therapeutics
|
◎ Target | Jason N. Butler not yet tracked | Market Outperform | $92.00→ $93.00+1.1% |
|
Aug 08
11:32 UTC
|
HAE
Haemonetics
|
◎ Target | Allen Gong ★★★☆☆ #1535 | Neutral | $62.00→ $86.00+38.7% |
|
Aug 08
11:32 UTC
|
HAE
Haemonetics
|
◎ Target | Joanne Wuensch ★★★★☆ #517 | Neutral | $79.00→ $92.00+16.5% |
|
Aug 08
11:32 UTC
|
GTM
ZoomInfo Technologies
|
◎ Target | Tyler Radke ★★★★☆ #357 | Sell | $2.00→ $2.50+25.0% |
|
Aug 08
11:32 UTC
|
GT
Goodyear Tire & Rubber
|
◎ Target | Rajat Gupta not yet tracked | Overweight | $9.00→ $10.00+11.1% |
|
Aug 08
11:32 UTC
|
GRT.UN
Granite Real Estate Investment Trust
|
◎ Target | firm only | Outperform | C$110.00→ C$106.00-3.6% |
|
Aug 08
11:32 UTC
|
GRT.UN
Granite Real Estate Investment Trust
|
◎ Target | firm only | Buy | C$106.00→ C$108.00+1.9% |
|
Aug 08
11:32 UTC
|
GRT.UN
Granite Real Estate Investment Trust
|
◎ Target | firm only | Buy | C$101.00→ C$103.00+2.0% |
|
Aug 08
11:32 UTC
|
GRDN
Guardian Pharmacy Services
|
◎ Target | Michael Wiederhorn ★★★★☆ #345 | Outperform | $43.00→ $49.00+14.0% |
|
Aug 08
11:32 UTC
|
GPCR
Structure Therapeutics
|
◎ Target | Samantha Semenkow ★★☆☆☆ #2597 | Buy | $100.00→ $97.00-3.0% |
|
Aug 08
11:31 UTC
|
GPCR
Structure Therapeutics
|
◎ Target | Jonathan Wolleben ★★★☆☆ #2175 | Market Outperform | $113.00→ $110.00-2.7% |
|
Aug 08
11:31 UTC
|
GMED
Globus Medical
|
◎ Target | Larry Biegelsen ★★★★☆ #604 | Overweight | $103.00→ $99.00-3.9% |
|
Aug 08
11:31 UTC
|
GMAB
Genmab A/S
|
◎ Target | Michael Schmidt ★★★☆☆ #2066 | Buy | $40.00→ $42.00+5.0% |
|
Aug 08
11:31 UTC
|
GLUE
Monte Rosa Therapeutics
|
◎ Target | Michael Schmidt ★★★☆☆ #2066 | Buy | $35.00→ $28.00-20.0% |
|
Aug 08
11:31 UTC
|
GLUE
Monte Rosa Therapeutics
|
◎ Target | Brian Cheng ★★★☆☆ #2146 | Overweight | $31.00→ $27.00-12.9% |
An analyst rating change is when a Wall Street brokerage updates its recommendation on a stock — an upgrade (e.g. Hold → Buy), a downgrade (e.g. Buy → Sell), or a price-target revision (raising or lowering the expected share price). This page lists the most recent changes across U.S. markets.
Where we independently track the analyst, each change shows our own star rating and accuracy rank, computed from real historical price performance — not the brokerage's own marketing. That lets you judge whether the analyst behind a call has actually been right before.
The feed refreshes several times a day, so new upgrades, downgrades and price-target changes appear the same day they are published. Each row shows the date and time we recorded it.
No. A rating change is one analyst's opinion, not investment advice. Track records vary widely — which is exactly why we attach each analyst's independent accuracy. Always do your own research.